RESUMO
Truncation of potent and selective dibasic inhibitors afforded monocharged inhibitors of human mast-cell tryptase. Using two classes of analogues as lead structures, several monocharged derivatives were identified with K(i) values ranging from 0.084 to 0.21 microM against the enzyme.
Assuntos
Guanidinas/química , Guanidinas/farmacologia , Piperazinas/química , Piperazinas/farmacologia , Serina Endopeptidases/efeitos dos fármacos , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Animais , Arginina/química , Benzamidinas/química , Sítios de Ligação , Disponibilidade Biológica , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Guanidinas/metabolismo , Humanos , Mimetismo Molecular , Piperazina , Piperazinas/metabolismo , Ratos , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/metabolismo , Relação Estrutura-Atividade , Triptases , UreiaRESUMO
A survey of charged groups and linkers for a series of symmetrical and unsymmetrical dibasic inhibitors is described, leading to several classes of potent and selective inhibitors. In particular, the benzamidine functionality was identified as the most potent charged group investigated.
Assuntos
Benzamidinas/química , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Mastócitos/enzimologia , Serina Endopeptidases/efeitos dos fármacos , Humanos , Relação Estrutura-Atividade , TriptasesRESUMO
The use of tetra-N-butylammonium fluoride (TBAF) as a mild and efficient reagent for the cyclodehydration of O-acyl amidoximes has been extended to the synthesis of 1,2,4-oxadiazoles on solid support. Argopore MB-CHO resin (Argonaut Technologies) was reductively aminated and subsequently acylated with 4-cyanobenzoyl chloride. Conversion of the nitrile to the amidoxime and acylation with a range of acid chlorides in parallel followed by treatment with TBAF under ambient conditions afforded a library of 3,5-disubstituted 1,2,4-oxadiazoles.
Assuntos
Oxidiazóis/síntese química , Compostos de Amônio Quaternário/química , Química Farmacêutica , Desenho de Fármacos , Oxidiazóis/químicaRESUMO
The synthesis and optimization of a novel class of reversible and active-site directed dibasic inhibitors of human mast cell tryptase are described. The compounds were shown to be both remarkably potent and selective for tryptase with Ki values for optimized inhibitors in the picomolar range.
Assuntos
Diaminas/síntese química , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/síntese química , Indutores da Angiogênese/antagonistas & inibidores , Sítios de Ligação , Ligação Competitiva , Diaminas/química , Diaminas/farmacologia , Desenho de Fármacos , Humanos , Nylons/síntese química , Nylons/química , Nylons/farmacologia , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Relação Estrutura-Atividade , Triptases , Xilenos/síntese química , Xilenos/química , Xilenos/farmacologiaRESUMO
Detailed structure activity relationships (SARs) for a series of dibasic human tryptase inhibitors are presented. The structural requirements for potent inhibitory activity are remarkably broad with a range of core template modifications being well tolerated. Optimized inhibitors demonstrate potent anti-asthmatic activity in a sheep model of allergic asthma. APC-2059, a dibasic tryptase inhibitor with subnanomolar activity, has been advanced to phase II clinical trials for the treatment of both psoriasis and ulcerative colitis.
Assuntos
Diaminas/síntese química , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/síntese química , Animais , Antiasmáticos/síntese química , Antiasmáticos/química , Antiasmáticos/farmacologia , Asma/tratamento farmacológico , Diaminas/química , Diaminas/farmacologia , Modelos Animais de Doenças , Humanos , Cinética , Estrutura Molecular , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Ovinos , Relação Estrutura-Atividade , TriptasesRESUMO
Determination of tight-binding inhibition constants by nonlinear least-squares regression requires sufficiently good initial estimates of the best-fit values. Normally an initial estimate of the inhibition constant must be provided by the investigator. This paper describes an automatic procedure for the estimation of tight-binding inhibition constants directly from dose-response data. Because the procedure does not require human intervention, it was incorporated into an algorithm for high-throughput screening of enzyme inhibitors. A suitable computer program is available electronically (http://www.biokin.com). Representative experimental data are shown for the inhibition of human mast-cell tryptase.
Assuntos
Inibidores Enzimáticos/análise , Serina Endopeptidases/metabolismo , Algoritmos , Automação , Ligação Competitiva , Quimases , Simulação por Computador , Inibidores Enzimáticos/farmacologia , Humanos , Cinética , Método de Monte Carlo , Serina Endopeptidases/efeitos dos fármacos , TriptasesRESUMO
In recent years, a role for the mast cell has emerged as a multifunctional, key effector cell in the immune system and may also serve to modulate the inflammatory response and immune-nervous system interactions. Mast cell stimulation leads to the secretion of several classes of mediators including proteolytic enzymes, most notably the trypsin-like serine proteinase, tryptase. Recent immunological and biological studies have demonstrated an association of mast cells and tryptase activity with a broad range of allergic and inflammatory conditions affecting nearly all the major systems of the human body. At present, there is sufficient evidence to strongly suggest that tryptase activity is a key aspect of some common and serious allergic and inflammatory diseases, particularly asthma. Due to the increasing prevalence of asthma in industrialized society, the inhibition of tryptase is viewed as a potentially important and novel therapeutic mechanism for disease intervention. Recent advances in the design of potent and selective inhibitors of tryptase provide a great deal of promise for the development of safe and effective drugs for the treatment of asthma and possibly a range of other diseases in the early 21st century.
RESUMO
Human tryptase is a structurally unique and mast cell specific trypsin-like serine protease. Recent biological and immunological investigations have implicated tryptase as a mediator in the pathology of numerous allergic and inflammatory conditions including rhinitis, conjunctivitis, and most notably asthma. A growing body of data further implicates tryptase in certain gastrointestinal, dermatological, and cardiovascular disorders as well. The recent availability of potent, and selective tryptase inhibitors, though, has facilitated the validation of this protease as an important therapeutic target as well. Herein, we describe the design and potency of four classes of selective tryptase inhibitors, of which the first three types are synthetic and the fourth is natural in origin: 1) peptidic inhibitors (e.g., APC-366), 2) dibasic inhibitors (i.e., pentamidine-like), 3) Zn(2+)-mediated inhibitors (i.e., BABIM-like), and 4) heparin antagonists (e.g., lactoferrin). These inhibitors have been tested in the airways and skin of allergic sheep. Aerosol administration of tryptase inhibitors from each structural class 30 minutes before, and 4 hours and 24 hours after allergen challenge, abolishes late phase bronchoconstriction and airway hyperresponsiveness in a dose-dependent manner. Moreover, intradermal injection of APC-366 blocks the cutaneous response to antigen. These studies provide the essential proof-of-concept for the further pursuit of tryptase inhibitors for the treatment of asthma, and perhaps other allergic diseases. Results from clinical studies with the first generation tryptase inhibitor APC-366, currently in phase II trials for the treatment of asthma, provide additional support for a pathological role for tryptase in this disease. Notable advances in the area of tryptase inhibitor design at Axys Pharmaceuticals, Inc. include a novel, zinc-mediated, serine protease inhibitor technology (described herein), and the discovery of a unique class of extremely potent and selective dibasic tryptase inhibitors. Independently, an X-ray crystal structure of active tryptase tetramer complexed with 4-amidinophenyl pyruvic acid has been reported. It is anticipated that these discoveries will further accelerate the design of structurally novel tryptase inhibitors as well as the development of new drugs for the treatment of mast cell tryptase-mediated disorders.